Information Library
Results for: Capital - Clinical Pharmacology - Phase II/III
In the complex environment of the New Health, Quintiles is committed to helping you succeed. At every stage of your product’s lifecycle, we are dedicated to delivering real results, being proactive in navigating issues and thinking of new solutions. Search our library today.
- Sort by:
- Recently Added
- Title
-
Intarcia and Quintiles Finalize Innovative Alliance
Press Release — December 13, 2011 – To speed development of a potential ground-breaking therapy for Type 2 diabetes – Intarcia Therapeutics, Inc., and Quintiles announced the signing of definitive agreements making Quintiles a financial and strategic partner for the global clinical development of Intarcia’s ITCA 650 (DUROS® continuous subcutaneous delivery of exenatide).
-
PharmAsia News Article Reprint
Media Coverage — March 1, 2010
Quintiles Asia Executives Say CROs Must Evaluate, Adjust To New Health Landscape: An Interview With PharmAsia News.
Page 1 of 1 (2 results)
